NRD
RCKT icon

Nebula Research & Development’s Rocket Pharmaceuticals RCKT Stock Holding History

Nebula Research & Development’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,780
Closed -$247K – 688
2025
Q2 		$247K Buy
+100,780
New +$511K 0.02% 836
2023
Q4 		– Sell
-21,435
Closed -$439K – 842
2023
Q3 		$439K Buy
+21,435
New +$390K 0.23% 157

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Nebula Research & Development's RCKT Position: Q3 2025 in Review

Nebula Research & Development sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 100,780 shares — an estimated $247K sold.

Nebula Research & Development first reported a position in RCKT in Q3 2023 and held it in 2 quarters. The position peaked at $439K in Q3 2023. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Nebula Research & Development reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 100,780 Rocket Pharmaceuticals shares in Q3 2025, an estimated $247K.
  • Nebula Research & Development first reported a position in Rocket Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Nebula Research & Development's Rocket Pharmaceuticals position peaked at $439K in Q3 2023.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.